We offer a variety of gene panels, both pre-made and custom. Some of our pre-made gene panels include the PrimBio Cancer Hotspot Panel, PrimBio Comprehensive Cancer Panel, PrimBio Inherited Disease Panel, PrimBio BRCA1/2 Panel, PrimBio Breast Cancer Panel, PrimBio Colorectal Cancer Panel, PrimBio AML Gene Panel, PrimBio AML Fusion Gene Panel, PrimBio Transcriptome Panel and the PrimBio Cancer Therapy Panel. Our company can also design custom gene panels as specified by the customer. Gene panel analysis includes library preparation, sequencing, alignment and variant calling. In-depth bioinformatics is also available upon request. All gene panel prices vary based on coverage criteria so please contact us for customized pricing. Each panel is sequenced using either Ion PGM or Ion Proton System Semiconductor Technology.
PrimBio Cancer Hotspot Panel includes hotspot regions from 50 of the most common oncogenes and tumor suppressor genes, with wide coverage of KRAS, BRAF and EGFR. This panel includes cancer "driver" genes and is designed to decipher the coding DNA sequences (CDS) of multiple gene families, including apoptosis genes, DNA repair genes, transcriptional regulators, inflammatory response genes and growth factor genes. The 2,800 variants covered by this panel are related to numerous cancers from colorectal to breast. This panel is also available as a CLIA certified service panel for clinicians who need genetic information to design a treatment plan for cancer patients. Researchers also find this panel useful when determining which mutations may be resistant to a specific drug.
PrimBio Inherited Disease Panel provides highly multiplexed targeted selection of all exons of over 300 genes that are mutated in many inherited diseases, according to NCBI ClinVar database. The Inherited Disease Panel was made by consulting with clinical molecular geneticists involved with inherited disease research and includes genes associated with the most common forms of inherited deafness, blindness, heart disease, Parkinson's disease, immunodeficiency, various ataxias, anemias, and treatable metabolic syndromes. Genes listed in the NIH Genetic Test Registry are included in this panel.
PrimBio Comprehensive Cancer Panel provides highly multiplexed target selection of genes important to cancer research. Encompassing over 50% of the Wellcome Trust Sanger Institute Cancer Gene Census, this is the most comprehensive cancer gene panel available. With all-exon coverage of 409 genes, the PrimBio Comprehensive Cancer Panel delivers fast, FFPE-compatible target selection for a broad survey of key cancer causing.
PrimBio BRCA1/2 Panel targets 167 amplicons to analyze the coding regions of both BRCA1 and BRCA2. Mutations in tumor suppressor genes BRCA1 and BRCA2 have been implicated in hereditary breast and ovarian cancer. A vast amount of research is currently being done today to better detect, treat, and prevent cancer in those who carry mutations in BRCA1 and BRCA2.
PrimBio BRCA1 and BRCA2 panel has also been tested and verified using numerous unique samples that have been previously characterized by capillary electrophoresis. Different types of variants including deletions, duplications and insertions near homopolymer regions were analyzed and all of the expected variants were detected with this panel. This rigorous testing validates that this panel is accurate and will have high utility when determining whether mutations in BRCA1 or BRCA2 in your samples may be associated with ovarian or breast cancer.
PrimBio BRCA1 and BRCA2 panel has also been tested and verified using numerous unique samples that have been previously characterized by capillary electrophoresis. Different types of variants including deletions, duplications and insertions near homopolymer regions were analyzed and all of the expected variants were detected with this panel. This rigorous testing validates that this panel is accurate and will have high utility when determining whether mutations in BRCA1 or BRCA2 in your samples may be associated with ovarian or breast cancer.
PrimBio Breast Cancer Panel targets breast cancer related genes, including: BRCA1/2, the most studied genes in inherited breast cancer, other candidate genes for inherited breast cancer, and susceptible genes that may have sporadic mutations in breast cancer. This is the most comprehensive breast cancer gene panel available. With complete exon coverage of 31 genes, the PrimBio Breast Cancer Panel delivers fast, FFPE-compatible target selection for analysis of key breast cancer related genes.
PrimBio Colorectal Cancer Panel detects mutations in 48 genes associated with increased risk for colorectal cancer. Colon cancer is defined as cancer that forms in the tissues of the colon while rectal cancer is defined as cancer that forms in the tissues of the rectum; since both form in the large intestine they are often synonymously referred to as colorectal cancer (CRC). Most colorectal cancers are adenocarcinomas. NCI estimated there were 96,830 new cases of colon cancer and 40,000 new cases of rectal cancer diagnoses in the United States in 2014. 50,310 deaths were attributed to colorectal cancer in the same year. While CRC is primarily associated with environmental factors, such as diet, 20% of CRC patients have a family history of the disease. The colorectal sequencing tests currently on the market are limited to detection of hereditary CRC gene variations. The PrimBio CRC Panel can detect early onset of colorectal cancer with germline and/or somatic gene mutations. The panel provides disease risk information and treatment guidance. Genes featured in this panel include APC, AKT1, MLH1, MSH2, MSH6, TP53, and more. The sequences of the exons and UTRs of these genes are analyzed to find clinically relevant variants.
PrimBio AML Gene Panel covers the entire exonic region of 63 key Acute Myeloid Leukemia (AML) cancer genes. AML is a heterogenous hematologic malignancy characterized by clonal expansion of myeloid blasts in the peripheral blood, bone marrow, as well as other tissues. AML is the most common form of acute leukemia among adults and consequently accounts for the largest number of annual deaths due to leukemias in the United States. The most commonly recognized risk factor for AML is environmental exposure to petrochemicals. Recently, however, there have been increasing incidents of diagnoses in individuals that endured previous tumor therapies, as a result of cytoxic agents that are commonly used in treatment of tumors.
PrimBio AML Fusion Gene Panel (RNA) Transcript fusions resulting from genomic rearrangement is an important class of somatic alteration, as a cancer initiating event and as a molecular therapeutic target for specific tumors. Fusion genes in AML patients are associated with leukemogenesis. Next-generation sequencing technology has opened up a systematic characterization of transcriptomes including gene expression, novel transcript, and fusion transcripts. The PrimBio AML Fusion Gene Panel is an RNA panel that covers 116 pairs of gene fusions related to AML, including RUNX1-RUNX1T1, BCR-ABL1, KAT6A-CREBBP, and more.
PrimBio Human Transcriptome Panel (RNA) We provide Ampliseq Human Transcriptome sequencing. This panel is used to measure expression levels of over 20,800 RefSeq genes. The panel targets 18,574 coding genes and 2,228 non-coding genes based on UCSC hg19 annotation. It is broadly applicable to research and clinical (expected December 2016) use. DNA extracted from FFPE tissue can be used with this panel.
PrimBio Cancer Therapy Panel examines the targets of FDA-approved targeted cancer therapy drugs, as well as the targets of pharmacogenomics. The gene targets are selected for their known association with cancer types and response or resistance to drugs. It covers 40 drug targets, oncogenes and pharmacogenomic genes such as: BRAF, CYB5R1, EGFR, KIT, KRAS, and more.
